Qaialdo® - References

All references link to appropriate papers

1.

Nova Laboratories Ltd. Qaialdo 10 mg/ml oral suspension (spironolactone). Summary of Product Characteristics (SmPC) [Internet]. Available from: https://www.medicines.org.uk/emc/product/100453/smpc.

2.

Batchelor HK, Marriott JF. Formulations for children: problems and solutions. Br J Clin Pharmacol. 2015;79(3):405-18.

3.

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Reflection Paper: Formulations of Choice for the Paediatric Population. July 2006 EMEA/CHMP/PEG/194810/2005.

4.

van Riet-Nales DA, Schobben AFAM, Vromans H, et al. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Child. 2016;101(7):662-669.

5.

Davies EH, Tuleu C. Medicines for children: a matter of taste. J Pediatr. 2008;153(5):599-604, 604.e1-2.

6.

Mendoza de Morales T, Sánchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe paediatric perennial allergic rhinitis. World Allergy Organ J. 2009;2(4):49-53.

7.

Elliott I, Mayxay M, Yeuichaixong S, et al. The practice and clinical implications of tablet splitting in international health. Trop Med Int Health. 2014; 19(7): 754–760.

8.

American Society of Health-System Pharmacists (ASHP) Spironolactone (Monograph) [Internet].Drugs.com. 2024. Available from: https://www.drugs.com/monograph/spironolactone.html

9.

Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021;11(1):323-335.

10.

Kirk R, Dipchand AI, Rosenthal DN, et al. The International food for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant. 2014;33:888-909.

11.

Chen C, Su D, Suyuan Q, et al. Severe Heart Failure and Outcomes in 121 Children With Dilated Cardiomyopathy: A Single-Center Retrospective Study from Southwest China. Research Square. 2022. 1-16.

12.

Pitt B, Pierard LA, Bilge A et al. Effectiveness of spironolactone added to anangiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldosterone Evaluation Study (RALES). Am J Cardiol 1996;78: 902-7.

13.

Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Current opinion in investigational drugs (London, England: 2000). 2008;9(9):963.